Evidence map›Paper›PMID 30478297›Full record

ArticleCell death & disease2018

Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition.

Eoin P McNeill, Robert W Reese, Abishek Tondon, Bret H Clough, Simin Pan, Jeremiah Froese, Daniel Palmer, Ulf Krause, David M Loeb, Roland Kaunas and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Shape Memory Polymer Scaffolds-Utility for In Vitro Osteogenesis of Canine Multipotent Stromal Cells.Journal of biomedical materials research. Part B, Applied biomaterials · 2024
    Article
  5. Review
  6. Article
  7. Multifunctional nanomaterialsMaterials today. Bio · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Eoin P McNeillDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, College Station, TX, 77845, USA.
Robert W ReeseDepartment of Biomedical Engineering, Texas A&M University, College Station, TX, 77843, USA.
Abishek TondonDepartment of Biomedical Engineering, Texas A&M University, College Station, TX, 77843, USA.
Bret H CloughDepartment of Medical Physiology, Texas A&M Health Science Center, Temple, TX, 76501, USA.
Simin PanDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, College Station, TX, 77845, USA.
Jeremiah FroeseDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, College Station, TX, 77845, USA.
Daniel PalmerDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, College Station, TX, 77845, USA.
Ulf KrauseInstitute for Transfusion Medicine and Transplant Immunology, University Hospital Muenster, Muenster, Germany.
David M LoebDepartments of Pediatrics and Developmental and Molecular Biology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, 3411 Wayne Avenue, Bronx, NY, 10467, USA.
Roland KaunasDepartment of Biomedical Engineering, Texas A&M University, College Station, TX, 77843, USA. rkaunas@tamu.edu.
Carl A GregoryDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, College Station, TX, 77845, USA. cgregory@medicine.tamhsc.edu.
Texas A&M Health Science Center · USTexas A&M University · USChildren's Hospital at Montefiore · USUniversity Hospital Münster · DE

Funding

Advanced Methods for Mimicking the Osteogenic Niche to Heal BoneR01AR066033 · NIAMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI GREGORY, CARL A. · 2014 to 2017
$1.3M
NIAMS NIH HHS R01 AR066033
6 · The paper itself

Abstract

Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and associated morbidity. Furthermore, the OL microenvironment can support survival of tumor cells and resistance to chemotherapy. Therefore, a deeper understanding of OL formation and MBD progression is imperative for the development of future therapeutic strategies. Herein, we describe a novel in vitro platform to study bone-tumor interactions based on three-dimensional co-culture of osteogenically enhanced human mesenchymal stem cells (OEhMSCs) in a rotating wall vessel bioreactor (RWV) while attached to micro-carrier beads coated with extracellular matrix (ECM) composed of factors found in anabolic bone tissue. Osteoinhibition was recapitulated in this model by co-culturing the OEhMSCs with a bone-tumor cell line (MOSJ-Dkk1) that secretes the canonical Wnt (cWnt) inhibitor Dkk-1, a tumor-borne osteoinhibitory factor widely associated with several forms of MBD, or intact tumor fragments from Dkk-1 positive patient-derived xenografts (PDX). Using the model, we observed that depending on the conditions of growth, tumor cells can biochemically inhibit osteogenesis by disrupting cWnt activity in OEhMSCs, while simultaneously co-engrafting with OEhMSCs, displacing them from the niche, perturbing their activity, and promoting cell death. In the absence of detectable co-engraftment with OEhMSCs, Dkk-1 positive PDX fragments had the capacity to enhance OEhMSC proliferation while inhibiting their osteogenic differentiation. The model described has the capacity to provide new and quantifiable insights into the multiple pathological mechanisms of MBD that are not readily measured using monolayer culture or animal models.

Indexed as

AnimalsBioreactorsBone DiseasesBone NeoplasmsCell Culture TechniquesCell DifferentiationCell ProliferationCoculture TechniquesExtracellular MatrixHumansIntercellular Signaling Peptides and ProteinsMesenchymal Stem CellsOsteogenesisOsteolysisTumor MicroenvironmentWnt Signaling PathwayDKK1 protein, humanIntercellular Signaling Peptides and Proteins

Identifiers

PMID30478297
PMCPMC6255770
OpenAlexW2902916891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.